// App-Quantinova.ai

: Determining biomarkers of response to docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating cell-free tumor DNA (ctDNA).

Researchers

Presenter

  • Daniel Khalaf

Principal Investigators

  • Cameron Herberts

  • Gillian Vandekerkhove

  • Matti Annala

  • Kevin Beja

  • Bernhard J. Eigl

  • Christian K. Kollmannsberger

  • Lucia Nappi

  • Joanna Vergidis

  • Alexander William Wyatt

  • Kim N. Chi

Medical Centers

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • Institute of Biosciences and Medical Technology, Tampere, Finland

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

  • Circulating DNA

Drug/Treatment

  • Docetaxel

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved